Eli Lilly and Company (BVMF:LILY34)
| Market Cap | 7.29T +50.5% |
| Revenue (ttm) | 447.86B +45.5% |
| Net Income | 142.86B +49.8% |
| EPS | 5.94 +50.7% |
| Shares Out | n/a |
| PE Ratio | 45.56 |
| Forward PE | 30.44 |
| Dividend | 0.78 (0.29%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 30,565 |
| Open | 271.90 |
| Previous Close | 276.31 |
| Day's Range | 269.80 - 276.36 |
| 52-Week Range | 142.00 - 281.75 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.
Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers.
Novo's Wegovy cuts BMI by 17.4% in obese children aged 6 to 11 in late-stage trial
Novo Nordisk's Wegovy cut BMI by 17.4% over 68 weeks in children aged 6 to 11 with obesity, according to full late-stage trial results reported by CNBC.
New research shows weight-loss drugs could be an effective option for children as young as 6 years old
Novo Nordisk's study of GLP-1s in children as young as 6 years old worked for shedding pounds but raised questions about growth rates.
Eli Lilly to acquire Calytrix Bio for up to $1.5B in cash
Calytrix Bio, a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms, announced a definitive agreement for Eli Lilly and Company (LLY) to acq...
Lilly to buy Calytrix Bio for up to $1.5 billion
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.
Eli Lilly price target raised to $1,550 from $1,400 at Barclays
Barclays analyst Emily Field raised the firm’s price target on Eli Lilly (LLY) to $1,550 from $1,400 and keeps an Overweight rating on the shares post the Q3 report. While…
Eli Lilly to present new data across portfolio at ObesityWeek 2026
Eli Lilly (LLY) and Company will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Washington, D.C. The presentations span…
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes...
Mapping the Market: Eli Lilly shares ready to rally again
Shares in Eli Lilly rose more than 70% from their 2026 low to the record high they hit on Thursday, and more gains could be in store, technical analysis indicates.
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company ...
Nvidia CEO Out — 10 Stocks To Buy Before S&P 500 Hits 8,000
Nvidia (NVDA) is down over 30% from the highs with CEO Jensen Huang stepping down, yet Blanke Schein Wealth Management CIO Robert Schein says the stock is still a buy. He also names Broadcom (AVGO), A...
The Big 3: JNJ, LLY, AAPL
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks i...
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Eli Lilly announces Orforglipron approved by China’s NMPA
Eli Lilly (LLY) China announced that its Orforglipron has been approved by China’s National Medical Products Administration, NMPA, for the launch of a Category 1 new drug, intended for adult…
China approves Eli Lilly's weight loss pill orforglipron
Eli Lilly on Thursday became the first drugmaker to have a GLP-1 weight-loss pill approved in China, giving it an edge over Danish rival Novo Nordisk (NOVOb.CO), opens new tab in the world's second-...
Eli Lilly announces 52-week results from TOGETHER-PsA Phase 3b open-label trial
Eli Lilly (LLY) announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz and Zepbound c...
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER...
Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their healt...
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
FDA orders blindness risk warning on weight loss drugs
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administrati...
Monday's Final Takeaways: LLY Foundayo Update & Lame Duck Congress Session Starts
There were some quiet market movers even as a lot of the oxygen was taken by Nvidia (NVDA) and its investigation into CEO Jensen Huang. Marley Kayden and Sam Vadas turn to their top takeaways from Mon...
Eli Lilly's Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
Lilly plans to seek FDA approval for Foundayo to treat sleep apnea, potentially giving its weight-loss pill an edge over Novo Nordisk's oral Wegovy.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.